new and emerging therapies for retinal diseases
DESCRIPTION
New and emerging therapies for retinal diseasesTRANSCRIPT
![Page 1: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/1.jpg)
New and Emerging Therapies for Retinal Diseases
Toufic Melki, M.D.
Richard Chiu, D.O.
Retina Centers of Washington
Locations in Rockville, Arlington, and Georgetown University
![Page 2: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/2.jpg)
Disclosures
• No financial interests to disclose
• Dr. Chiu has been a consultant to Alimera Sciences
![Page 3: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/3.jpg)
Outline
I. Diabetic Macular Edema• A. Anti-VEGF therapies• B. Corticosteroids and role of inflammatory mediators in DR
• 1. Ozurdex• 2. Iluvien
II. AMD• A. Sustained delivery devices• B. Platelet derived growth factor inhibition (anti-PDGF therapy)• C. Gene therapy• D. Complement cascade inhibition• E. Squalamine topical therapy
III. RVO• A. Anti-VEGF therapies and differences with DME, wAMD therapy• B. Corticosteroids
IV. Case presentations
![Page 4: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/4.jpg)
Diabetic macular edema
• 26 million Americans with diabetes
• 2 million new cases of DM diagnosed every year
• 19% of current diabetics are undiagnosed
• About 10% of patients with DM develop DME in their lifetime
• 72,000 new cases of DME diagnosed each year
![Page 5: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/5.jpg)
Prevalence of diagnosed DM in US adults
2004 2008
http://apps.nccd.cdc.gov/ddtstrs/default.aspx
![Page 6: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/6.jpg)
Prevalence of diagnosed DM in Maryland adults
http://apps.nccd.cdc.gov/ddtstrs/default.aspx2004
2008 20112004
0 - 6.3
6.4 – 7.5
7.6 – 8.8
8.9 – 10.5
≥ 10.6
![Page 7: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/7.jpg)
Diabetic macular edema
• “Standard of care”
• Focal/grid laser
• ETDRS
• Clinically significant diabetic macular edema
• Focal/grid laser decreased 3-year risk of moderate vision loss from 24% to 12%
• Visual acuity did not improve
![Page 8: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/8.jpg)
Anti-VEGFS
![Page 9: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/9.jpg)
Ranibizumab(Lucentis) for DME
• FDA approved for diabetic macular edema (DME) in August 2012
• Monthly injection
• 0.3 mg dose (different than 0.5 mg used for RVO and AMD)
• $1100 per dose (vs $1900 for 0.5 mg)
![Page 10: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/10.jpg)
RIDE and RISE studies
• 36 month Phase III studies for MONTHLY injection of ranibizumab
• 759 patients
• VA ranging from 20/40 to 20/320
• OCT > 275 microns
• Focal laser allowed at 3 months
![Page 11: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/11.jpg)
RISE
Mean
change
ETDRS
letters
15 or more
letters
gained
36 mo 36 mo
Sham +4.7 19.2%
0.3 mg +10.5 36.8%
Mean
change
ETDRS
letters
15 or more
letters
gained
36 mo 36 mo
Sham +4.3 22.0%
0.3 mg +14.2 51.2%
RIDE
Sham group received Lucentis from mo 24-36
![Page 12: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/12.jpg)
RIDE/RISE
Lucentis 0.3 mg Sham
Received macular laser 37.6% 72.0%
Mean # of laser treatments 0.7 1.7
Received panretinal laser 0.8% 11.7%
Progression of DR severity 11.2% 33.8%
24 month data
![Page 13: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/13.jpg)
RIDE/RISE
• Not so impressive findings• 23% treated patients still had central macular thickness of ≥ 250 microns
• 40% had not achieved VA ≥ 20/40
![Page 14: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/14.jpg)
In the real world…
• Treatment burden• Cost
• Patient tolerance
• Do we really need to inject every month?• DRCR-net Protocol I
![Page 15: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/15.jpg)
Aflibercept (Eylea)
• FDA approved for diabetic macular edema (DME) in July 2014
• 2 mg dose (same as RVO and AMD dose)
• Monthly injection x 5 doses, Q 2 months thereafter
• $1850 per dose
![Page 16: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/16.jpg)
VIVID (EU and Japan)/VISTA (US) studies
• Phase III studies comparing Eylea 2.0 mg MONTHLY and Q2 MONTHS (after 5 initial monthly injections) to sham
• VIVID 461 patients, VISTA 466 patients
• 3 year study
• “Rescue” laser given if VA declined >=15 letters at any 1 visit or >= 10 letters in 2 consecutive visits
![Page 17: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/17.jpg)
VISTA
Mean
change
ETDRS
letters
15 or more
letters
gained
12 mo 12 mo
Sham +1.2 9.1%
Monthly +10.5 32.4%
Q 2mo (after
5 monthly)
+10.7 33.3%
VIVID
Mean
change
ETDRS
letters
15 or more
letters
gained
12 mo 12 mo
Sham +0.2 7.8%
Monthly +12.5 41.6%
Q 2mo (after
5 monthly)
+10.7 32.4%
![Page 18: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/18.jpg)
Bevacizumab (Avastin)
• $42 per dose for intravitreal
• Cost of treatment for colon CA is $40,000-100,000 annually
• Efficacy in wAMD demonstrated to be comparable in CATT study
![Page 19: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/19.jpg)
BOLT study
• 24 month prospective study for bevacizumab (Avastin)• Mean change in BCVA
• Treatment (q 6 weeks) +8.6 letters
• Laser -0.5 letters
• 15 letter or more gain• Treatment group 32%
• Laser group 4%
![Page 20: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/20.jpg)
DRCR.net Protocol T
• NIH sponsored studying comparing 660 patients randomly assigned to treatment with Eylea, Lucentis, and Avastin• Identical retreatment criteria
• AAO 2014• “Teaser” for 12 month data
• Eylea treated patients significantly better by 2 ETDRS letters than Lucentis and Avastin treated patients
• Eylea treated patients received one fewer injection than Lucentis and Avastintreated patients
• Rate of ATE (arteriothromboembolic events) was 2% Eylea, 4% Avastin, 5% Lucentis
• Results pending verification prior to publication
![Page 21: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/21.jpg)
Corticosteroids
![Page 22: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/22.jpg)
Corticosteroids
• Role of inflammatory cytokines BESIDES VEGF in DR• IL-6
• MCP-1
• Anti-VEGF therapy may not fully address the pathophysiology of DR
VEGF Inflammatory cytokines
Anti-VEGF *** *
Corticosteroid * ***
![Page 23: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/23.jpg)
Fluocinolone (Iluvien)
• Alimera Sciences
• Non-biodegradable implant, releases 0.2 mcg/day
• 3 year duration of effect
• Previously rejected by FDA in 2011 citing adverse events (IOP, glaucoma)
• In use in several E.U. countries
• FDA approval September 2014 for DME previously treated with corticosteroids s significant IOP elevation
• Available in US 1st quarter 2015, cost $8000 (?)
![Page 24: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/24.jpg)
FAME study
• Two 3 year Phase III studies for Iluvien
• 15 letter or more gain• Treatment group 28.5-32.4%
• Sham 13.4%
• 82-88% of phakic patients received cataract surgery
• 38-42% required IOP lowering meds
• 4.8-8.1% required glaucoma surgery
![Page 25: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/25.jpg)
Dexamethasone (Ozurdex)
• Injectable biodegradable intravitrealimplant, 3-6 mo duration of effect
• $1300 per dose
• FDA approved for DME June 2014
![Page 26: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/26.jpg)
MEAD study
• 3 year phase III study
• Retreatment allowed q 6 mo
• Mean 4.1 injections over 3 year study period
• Adverse outcomes• 59% treated patients needed cataract surgery (vs 7% in sham group)
• 41% required IOP lowering medication
• 0.7% needed glaucoma filtration surgery
![Page 27: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/27.jpg)
MEAD study – pseudophakic/anticipated cataract surgery participants
Ozurdex Sham
% of pts with ≥ 15 letter gain 23.3 10.9
Mean change in VA from baseline +6.5 +1.7
% achieving ≥ 20/40 VA 29.1 17.8
![Page 28: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/28.jpg)
Corticosteroids
• Consider using if/when DME patients are:
• Pseudophakic or anticipating cataract surgery
• Post-vitrectomy
• Unable to maintain near monthly follow-up/injections frequently required for anti-VEGF treatment
• Poorly responsive or tachyphylactic to anti-VEGF monotherapy
![Page 29: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/29.jpg)
AMD
• How far we have come
• What do we do (with what we have)
• Where we are going
![Page 30: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/30.jpg)
AMD – How far have we come
• Bloch SB, et al. Am J Ophthalmol 2012; 153: 209-213
• Population based observational study, Denmark
• Incidence of legal blindness from AMD decreased by 50% from 2000-2010
• Most of the decrease occurring after 2006 (i.e. after introduction of anti-VEGF therapy)
![Page 31: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/31.jpg)
AMD – How far have we come
• MARINA study
• Monthly ranibizumab (Lucentis) injection x 2 years
• +10.7 ETDRS letters
• -14.9 letters with sham
• -9.8 letters with photodynamic therapy (ANCHOR)
![Page 32: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/32.jpg)
AMD – How far we have come
• VIEW1/VIEW2• Phase III study comparing aflibercept (Eylea) to ranibizumab (Lucentis)
• Year 1: Eylea q 8 weeks (after 3 initial monthly doses) vs Lucentis q 4 w
• Year 2: PRN with monthly evaluation
Mean change ETDRS
letters at 2 years
Total injection in the 2nd
year
Total injections over 2
years
Eylea q 8 w +7.6 4.2 11.2
Lucentis q 4 w +7.9 4.7 16.5
![Page 33: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/33.jpg)
AMD – What do we do (with what we have)
• CATT
• 2 key questions • Comparison of bevacizumab (Avastin) with ranibizumab (Lucentis)
• Monthly vs PRN dosing of each
• 24 month results• Monthly dosing favored over PRN
• 2.4 letters
• Switching to PRN after 1 year of monthly injection resulted in -2.2 letters over continued monthly dosing
• VA outcomes slightly favor Lucentis (1.4 letters) but was not statistically significant
![Page 34: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/34.jpg)
• IVAN (“British CATT”)
• 2 key questions
• Comparison of bevacizumab (Avastin) with ranibizumab (Lucentis)
• Continuous (monthly) vs discontinuous (PRN)
• 24 month results (The Lancet, 382: 1258-1267)
• Bevazicumab (-1.37 letters) was “neither inferior nor non-inferior to ranibizumab”
• Discontinuous (-1.63 letters) was “neither inferior nor non-inferior to continuous”
AMD – What do we do (with what we have)
![Page 35: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/35.jpg)
AMD- What do we do (with what we have)
• HARBOR study• Ranibizumab (Lucentis)
• 0.5 mg vs 2.0 mg (“high dose”)
• Monthly vs PRN after 3 monthly doses
• Retreatment if OCT demonstrated fluid or if VA decreased by ≥ 5 letters
• 24 month results
• No significant difference between 0.5 mg and 2.0 mg dose
• In year 2, PRN treated group had similar visual outcomes with average of 9.9 weeks between injections
Mean
change
ETDRS
letters at 2
years
15 or
more
letters
gained
(%) at 1
year
Total # of
injections
over 2
years
Monthly +9.1 34.5 22.0
PRN +7.9 30.2 13.3
0.5 mg dose
![Page 36: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/36.jpg)
AMD - Where are we going
• Sustained release• Quest for the “Everlasting Gobstopper”
![Page 37: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/37.jpg)
AMD – Where are we going
• Encapsulated Cell Technology (Neurotech)• Genetically engineered RPE cells line which can be modified to produce
specified protein
• Encapsulated non-biodegradable delivery device
• Initial device produced ciliary neurotrophic factor (CNTF) for retinitis pigmentosa and dry AMD
• Adaptable to produce all classes of biotherapeutics (anti-VEGF, PDGF, etc.)
![Page 38: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/38.jpg)
Encapsulated cell technology (ECT)
![Page 39: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/39.jpg)
AMD – Where are we going
• Wet AMD/ECT• VEGF receptor decoy (NT-503) – Affinity for VEGF similar to aflibercept
(Eylea)
• Phase 1• Dose escalation studies
• Double implant vs single
• 2 line gain with double implant at 10 months
• 150 micron decrease in central subfield on OCT with double implant vs 50 micron with single
• Phase 2 study with new generation implant with 2-3x release rate
• Future implants could combine more than 1 therapy (e.g. anti-VEGF + anti-PDGF)
![Page 40: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/40.jpg)
AMD – Where are we going
• Nanostructured Tethadur (pSivida)• Implantable silicone porous silicone wafer
• Diameter of pores “tuned” to affect sustained release
• “Tube of tennis balls”
• Faster release with ping pong balls
• Slower release with tennis balls
• Drug (e.g. Avastin, Eylea, etc) withdrawn from vial and mixed with Tethadurparticles
• Animal studies – sustained release of bevacizumab for 6 months
![Page 41: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/41.jpg)
Nanostructured Tethadur
![Page 42: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/42.jpg)
AMD – Where are we going
• Port delivery system (PDS)• Developed by Genentech in collaboration with ForSight VISION 4
• Subconjunctival implant, placed in pars plana
• 10 minute procedure
• Minimally invasive office based refill procedure
• Phase 1 study• Lucentis
• Average improvement of 2 lines at 1 year
• Average 4-5 refills in 12 months
• Phase 2 underway• Higher dose
• Goal of 4 month interval
![Page 43: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/43.jpg)
AMD – Where are we going
• MicroPump (Replenish)• Battery
• Drug reservoir chamber
• Refill port accessible with transconjunctival 31 g needle
• Intraocular canula releases microdose into vitreous cavity
• Phase 1 study
![Page 44: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/44.jpg)
AMD – Where are we going
•Beyond VEGF • Anti-Platelet derived growth factor (anti-PDGF)
• Gene Therapy/Stem Cell
• Topical therapy
![Page 45: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/45.jpg)
Anti-platelet derived growth factor therapy
• The problem with anti-VEGF monotherapy• Withdrawal or undertreatment results in recurrent neovascularization in a
vast majority because:
• Anti-VEGF treatment decreases vascular permeability…
• BUT does not cause regression of the NV complex
![Page 46: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/46.jpg)
Anti-PDGFs
![Page 47: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/47.jpg)
Platelet derived growth factor (PDGF)
• What’s in a neovascularcomplex?• Endothelial cells
• “bricks and mortar”
• Expresses PDGF• Pericyte recruitment
• Pericytes• “armor against anti-VEGF”
• Promotes endothelial cell survival through chemical signaling
• Inflammatory cells
Anti-VEGF therapy
![Page 48: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/48.jpg)
How can we dismantle NV?
![Page 49: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/49.jpg)
PDGF antagonist (E10030), Ophthotech
![Page 50: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/50.jpg)
Combined anti-VEGF/anti-PDGF treatment
![Page 51: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/51.jpg)
Fovista (Ophthotech)
Pericyte Anti-VEGF PDGF FovistaFovista bound
to PDGFFovista + Anti-VEGF
combination therapy
Pericyte coverage protects NV complex from anti-VEGF induced disruption
Fovista is injected Fovista binds PDGF leading to stripping away of pericytes
Regression of NV complex!
Ophthotech.com
![Page 52: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/52.jpg)
Fovista (Ophthotech)
• Phase 2 study• 24 week endpoint
• Comparison of Fovista/Lucentis vs Lucentis monotherapy
• +10.6 letters for combination therapy
• +6.5 for Lucentis monotherapy
• Development of subretinal fibrosis
• 10% in combination group
• 51% in Lucentis monotherapy group
• Phase 3 study underway
![Page 53: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/53.jpg)
Anti-PDGF
• Also being developed by:• Neurotech using Encapsulated Cell Technology (ECT) implants
• MedImmune as a combination anti-VEGF/anti-PDGF injection with goal of lasting 6 months
• REGN2176-3 (Regeneron) combination with aflibercept (Eylea) in Phase 1 studies
• DE-120 (Santen) anti-VEGF/anti-PDGF in Phase 1 studies
![Page 54: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/54.jpg)
Gene Therapy
![Page 55: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/55.jpg)
Gene therapy
• Therapy in which genetic material is introduced into cells to effect protein transduction by the cells
1. Compensate for structurally abnormal or missing genes
2. Also can be used to induce target host cells to secrete a naturally occurring or engineered therapeutic protein (as alternative to repeated injections)
![Page 56: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/56.jpg)
Gene therapy
• Desirable features of viral vectors1. Able to introduce and transfer target cells with cDNA
2. No activation of immune response
3. Vector incapable of causing disease
4. Much of the vector’s genetic material can be replaced by the therapeutic gene
• Adeno-associated virus (AAV)
![Page 57: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/57.jpg)
Gene therapy
![Page 58: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/58.jpg)
Gene therapy
• Advantages of the eye• It’s small (i.e. low volume, large effect)
• Immunologically privileged • Low systemic side effects
• Direct delivery of therapy
![Page 59: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/59.jpg)
Ongoing retinal gene therapy trials
• Wet AMD
• Leber’s congenital amaurosis
• Stargardt’s disease
• Choroidemia
• Usher syndrome
• Retinitis pigmentosa
![Page 60: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/60.jpg)
AAV2-sFlt01
• Intravitreal Therapy (Genzyme/Sanofi)
• Induces expression of a modified VEGF receptor 1 (VEGFR1)
• Preclinical primate models
• Binds VEGF with high affinity
• Expresses VEGFR1 for at least 18 months after 1 injection
![Page 61: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/61.jpg)
AAV2-sFlt01
• Subretinal therapy (Avalanche Biotech)• Phase 1 study (6 pts) treated with low/high dose plus control arm
• 2 initial monthly Lucentis injections
• Day 380
Change in ETDRS letters # of rescue Lucentis
Low dose +8.7 0.33
High dose +12.5
Control -3.5 3.00
![Page 62: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/62.jpg)
AAV2-sFlt01
• http://permalink.fliqz.com/aspx/permalink.aspx?at=2315379b3136443fa353b26aaf11d582&a=375d1defb6aa477988c6708adf47c1e7
![Page 63: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/63.jpg)
Stem cell transplantation
• hESC (human embryonal stem cell)• Pluripotent (any germ layer)
• Derived from human embryos (blastocyst stage) 5 days after feritilization
• Results in destruction of embryo
• iPSC (induced pluripotent stem cell)• Derived from adult cells
• More tumorigenic than ESC (teratoma formation)
• Amniotic and cord blood stem cells• Multipotent
![Page 64: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/64.jpg)
hESC
5 Days
![Page 65: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/65.jpg)
Stem cell transplantation
• Ocata Therapeutics (formerly Advanced Cell Technology)
• Phase 1/2 studies – primary endpoint of safety and tolerability• Mean 22 months follow up, 3 dose cohorts (50K, 100K, 150K cells)
• Human embroynal stem cell (hESC) derived RPE cells
• 9 pts c Stargardt’s/9 pts c dry AMD (VA ≤ 20/400 in worse vision cohorts and ≤ 20/100 in better vision cohort)
• Wills, Bascom Palmer, UCLA
![Page 66: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/66.jpg)
Stem cell transplantation
• Safe, well tolerated (i.e. no rejection by immune system or teratoma formation)
• Stargardt’s: HM to 20/800
• dAMD: +7 ETDRS letters
N=18 Significantly
improved
Stable to
insignificantly
improved
Worsened
Visual acuity 10 7 1
![Page 67: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/67.jpg)
Complement cascade inhibition
• Geographic atrophy• Loss of macular RPE
• Pathophysiology
• Complement cascade hyperactivity (?)
• Chronic inflammation/overactivation of immune system in macula
• Complement factor H and I (CFH and CFI) work together to deactivate the cascade that triggers inflammatory response and cell death
• Genetic polymorphisms in CFH, CFH are associated with advanced AMD risk
![Page 68: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/68.jpg)
Complement cascade inhibition
• Lampalizumab (Genentech)• Inhibits alternative complement cascade by targeting
Complement Factor D
• MAHALO study, Phase 2 study• Sham vs monthly injection • Primary endopoint – change in GA area• Relationships between genetic polymorphisms with
treatment assessed• RESULTS:
• 20.4% reduction in GA progression in ALL lampalizumabtreated pts
• 44% reduction in GA progression in pts positive for CFI biomarker
• 57% of DNA tested pts were CFI+
• Phase 3 underway
![Page 69: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/69.jpg)
![Page 70: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/70.jpg)
Topical therapy
![Page 71: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/71.jpg)
Squalamine
• Originally derived from dogfish shark liver, now chemically synthesized
• Inhibits both VEGF and PDGF
• Initial wet AMD trials• Intravenous infusion
• Weekly x 4 weeks, monthly thereafter
• Effective gains in VA/maintenance of VA
• RAPID plasma clearance – posterior ocular therapeutic concentration requires > 1 IV infusion treatments per week
![Page 72: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/72.jpg)
Squalamine eye drops
• Ohr Pharmaceutical• Rapid uptake
• Trough levels >> threshold to inhibit angiogenesis
• Phase 2 IMPACT study
• 9 month data
• Topical squalamine/Lucentis injection vs sham/Lucentis injection
• Initial Lucentis injection and PRN injection thereafter
VA gain (ETDRS
letters)
≥ 15 letter gain Mean # of injections
Squalamine + Lucentis +10.4 48.3% 6.2
Lucentis monotherapy +6.3 21.2% 6.4
![Page 73: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/73.jpg)
Retinal vein occlusion (RVO)
• Aflibercept (Eylea)• Regeneron
• FDA approved for BRVO, October 2014
• FDA approved for CRVO, September 2012
• VIBRANT study, Phase 3
% gaining ≥ 15 ETDRS letters Mean gain in ETDRS letters
Eylea 53% +17.0
Laser (control) 27% +6.8
![Page 74: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/74.jpg)
Retinal vein occlusion (RVO)
• Similar results for the other anti-VEGFs• Lucentis 0.5 mg (CRUISE/BRAVO)
• Avastin
![Page 75: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/75.jpg)
Inflammatory cytokines, VEGF and RVO
![Page 76: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/76.jpg)
Combination treatments
• Intravitreal bevacizumab(Avastin)/dexamethasone (Ozurdex)
• Maturi, et al. Clin Ophthalmol. 2014; 8: 1057–1064• 6 month study
• Initial Avastin followed by Ozurdex vs sham
• PRN Avastin injection q month
Mean # of bevacizumab
reinjections
Combination group 2.0
Bevacizumab alone 3.0
![Page 77: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/77.jpg)
Maturi, et al. Clin Ophthalmol. 2014; 8: 1057–1064
![Page 78: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/78.jpg)
Conclusions
• Most patients with wet AMD, DME, RVO can now benefit from effective and proven treatments
• Many patients still fall through the cracks• Poorly responsive
• Undertreated
• Overall burden of treatment
• Knowledge is power
![Page 79: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/79.jpg)
DME
20/160 20/60
20/30 20/30
Baseline + 1 year
+ 2 years + 3 years
63 y.o.
female with
DM2
• Initial
monthly
Avastin
injection
• Subtenons
kenalog
injection
• Retreated
PRN
• IVA q2
months
• STK q 3-4
months
![Page 80: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/80.jpg)
67 y.o. male with
DM2
• Initial monthly
Avastin injection
• Subtenons kenalog
injection
• Retreated PRN
• IVA q 2-4 months
• STK q 3-4 months
Baseline
+ 1 year
+ 2 years
20/200
20/40
20/30
DME
![Page 81: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/81.jpg)
CRVO56 year old male with
BRVO
• Did not show for
scheduled Avastin
injection for 1 month
20/60
20/100
20/30
AVASTIN #1
AVASTIN #2
Baseline
+ 1 month
+ 2 months
![Page 82: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/82.jpg)
CRVO
46 y.o. male
with CRVO
• Initial
observation
no edema
Baseline
20/40
2 months
4+ months
20/80AVASTIN #1
20/60AVASTIN #2 +
STKAVASTIN #3
5+ months
AVASTIN #4
20/30
20/30 20/40AVASTIN #5
6+ months 7+ months
![Page 83: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/83.jpg)
wAMD77 y.o. female
with classic
CNVM
![Page 84: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/84.jpg)
wAMDBaseline 1 month
2 months 3 months
20/400 20/200
20/200 20/100
AVASTIN #1 AVASTIN #2
AVASTIN #3 AVASTIN #4
![Page 85: New and emerging therapies for retinal diseases](https://reader031.vdocument.in/reader031/viewer/2022020116/559c88f01a28ab58488b4884/html5/thumbnails/85.jpg)
Thank you